Original language | English (US) |
---|---|
Pages (from-to) | e15-e17 |
Journal | Biological psychiatry |
Volume | 67 |
Issue number | 2 |
DOIs | |
State | Published - Jan 15 2010 |
ASJC Scopus subject areas
- Biological Psychiatry
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Biological psychiatry, Vol. 67, No. 2, 15.01.2010, p. e15-e17.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Reply Regarding "Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression
T2 - A Multisite Randomized Controlled Trial"
AU - O'Reardon, John P.
AU - Solvason, H. Brent
AU - Janicak, Philip G.
AU - Sampson, Shirlene
AU - Isenberg, Keith E.
AU - Nahas, Ziad
AU - McDonald, William M.
AU - Avery, David
AU - Fitzgerald, Paul B.
AU - Loo, Colleen
AU - Demitrack, Mark A.
AU - George, Mark S.
AU - Sackeim, Harold A.
N1 - Funding Information: Dr. Isenberg has received grant support from the NIMH and Neuronetics; he is currently a full-time medical director at Wellpoint. Funding Information: Dr. Loo has received research support from the National Health and Medical Research Council (Australia), Neuronetics, New South Wales Schizophrenia Fellowship, Pfizer Neuroscience. Funding Information: Dr. Sackeim has received research support from the Cyberonics, MECTA, NARSAD, National Institute of Mental Health, and has acted as a consultant to Cyberonics, Eli Lilly, Magstim, MECTA, Neuronetics, NeuroPace, Novartis, and Pfizer. Funding Information: Dr. McDonald reports that he serves on the Executive Board of the Georgia Psychiatric Physicians Association and is Director of the Fuqua Center for Late-Life Depression, which advocate for geriatric psychiatry. Dr. McDonald is a member of the American Psychiatric Association (APA) task force on electroconvulsive therapy (ECT) and a member of the APA Council on Research. He reports consultant/speaker honorarium from Myriad, Bristol-Myers Squibb, and Janssen. He has received grant support from Boehinger Ingelheim and Neuronetics and was an investigator in a trial sponsored by Janssen. He is presently principal investigator (PI) on an NIMH study that uses Neuronetics' transcranial magnetic stimulators. Dr. McDonald works for Emory University, which holds a patent for the transcranial magnetic stimulator that is used in the NIMH trial. He is also in an National Institute of Neurological Disorders and Stroke (NINDS) trial that is evaluating medication donated by Smith Kline (Paxil Controlled Release [CR]) and Wyeth (Effexor Extended Release [XR]). Funding Information: Dr. Fitzgerald has received research support from the National Health and Medical Research Council (NHMRC), National Alliance for Research on Schizophrenia and Depression (NARSAD), Beyond Blue, and Neuronetics, Ltd. Funding Information: Research Grant scheme, NARSAD, and Rebecca Cooper Medical Research Foundation.
PY - 2010/1/15
Y1 - 2010/1/15
UR - http://www.scopus.com/inward/record.url?scp=71649087928&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=71649087928&partnerID=8YFLogxK
U2 - 10.1016/j.biopsych.2009.06.027
DO - 10.1016/j.biopsych.2009.06.027
M3 - Letter
C2 - 19914602
AN - SCOPUS:71649087928
SN - 0006-3223
VL - 67
SP - e15-e17
JO - Biological psychiatry
JF - Biological psychiatry
IS - 2
ER -